• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
3-Bromo-4-fluorobenzaldehyde
5-Methyl-1,3,4-oxadiazol2(3H)-one
4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride
4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine
3-Pyridinecarboxaldehyde
Ethyl 3 Fluorobenzoate

Samsung Bioepis gets nod for sale of biosimilar drug in Europe

firstwordpharmaMarch 06, 2019

Tag: Samsung Bioepis , NOD , biosimilar drug

  • Samsung Bioepis has won European approval of a 420-mg dosage of Ontruzant, a biosimilar of Roche's Herceptin, The Korea Herald reported Tuesday.

  • The drugmaker previously gained clearance for the 150-mg dosage in 2017.

  • "There is demand for both 150 mg and 420 mg products in Europe," a company official remarked, adding "we expect to provide more treatment opportunities for patients by expanding our product portfolio."

Register as Visitor to CPhI China 2019!

Previous:Johnson & Johnson's Spravato garners FDA approval for treatment-resistant depression

Next:Novo Nordisk Pharma Ltd. partners with Health2Sync in Japan, bringing digital diabetes management to healthcare providers and patients

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Samsung Bioepis gets nod for sale of biosimilar drug in Europe | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

Chenodeoxycholic Acid(Cas no:474-25-9)

Chenodeoxycholic Acid(Cas no:474-25-9)
Cyclopropylboronic acid methyliminodiacetic acid anhydride

Cyclopropylboronic acid methyliminodiacetic acid anhydride
Minodronic acid Intermediate B

Minodronic acid Intermediate B
Ganoderma Capsule

Ganoderma Capsule
diethyl iminodiacetate

diethyl iminodiacetate
Best Quality Standard supply Chenodeoxycholic acid CAS:474-25-9

Best Quality Standard supply Chenodeoxycholic acid CAS:474-25-9
Ganoderic acid D2

Ganoderic acid D2
Ganoderma Lucidum Extract

Ganoderma Lucidum Extract
Ganoderma Lucidum Extract

Ganoderma Lucidum Extract
Ganodema P.E.

Ganodema P.E.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service